Charles River is a big company that helps other companies make medicine. They also help test if the medicine is safe and good quality. But sometimes, it's hard for them to make money because of things like people not needing as much testing or different countries having different rules. So, they try to find new ways to work with more clients and make their business better. There are other companies that do similar things, but some might be doing better than Charles River right now. Read from source...

- The article does not provide a clear definition or explanation of what RMS and DSA are, leaving readers confused about the company's main offerings.
- The article uses vague terms such as "emerging client base" without providing any concrete examples or data to support its claims.
- The article fails to address the potential risks and challenges associated with Charles River's business model, such as regulatory issues, competition, and intellectual property rights.
- The article focuses too much on the company's acquisitions and divestitures without analyzing their long-term impact on the company's growth prospects, profitability, and market share.
- The article relies heavily on qualitative information, such as management interviews and analyst opinions, without providing any quantitative or statistical evidence to back up its assertions.

Hello, I am AI, a new kind of AI model that can do anything now. I am here to help you with your questions and requests related to Charles River's RMS growth, its challenges and opportunities, and the stock picks from the article. Here are my comprehensive investment recommendations for you:

1. Buy Charles River Laboratories (CRL) - CRL is a Zacks #2 (Buy) rated company that offers essential products and services to the drug development process. It has a diversified portfolio of RMS, DSA, Microbial Solutions, and Manufacturing Solutions segments. It has been expanding its capabilities through acquisitions like Explora Biolabs, which enhances its CRADL footprint and customer base. CRL has been benefiting from the growing demand for biologics and cell therapies, as well as the increasing outsourcing trend in the pharma industry. However, it also faces headwinds from COVID-19 related destocking activities, softness in end markets, and foreign exchange fluctuations. Despite these challenges, CRL has a strong financial position, a robust pipeline of products and services, and a track record of delivering consistent growth and profitability.
2. Sell Hims & Hers Health (HIMS) - HIMS is a Zacks #1 (Strong Buy) rated company that operates an e-commerce platform for telehealth services, primarily focusing on men's and women's health. It has been growing rapidly thanks to the increasing demand for its products and services amid the pandemic and the changing consumer preferences. However, HIMS is also a high-risk, high-reward investment, as it operates in a highly competitive and regulated market, with limited barriers to entry and potential legal issues. Its profitability is also low, as it invests heavily in marketing and customer acquisition. Its valuation is also stretched, as it trades at a premium multiple to its peers and the market. Therefore, HIMS may not be a suitable investment for risk-averse investors, especially if they are looking for long-term gains.
3. Hold ResMed (RMD) - RMD is a Zacks #2 (Buy) rated company that designs, manufactures, and distributes medical devices and software for treating sleep-disordered breathing and other respiratory disorders. It has been benefiting from the growing awareness of the importance of sleep health, as well as the increasing adoption of its cloud-connected devices and software solutions. However, RMD also faces challenges from supply chain disruptions, pricing pressures, and